Bionapcfa.blogspot.com

Press Announcements > FDA approves new treatment for late-stage breast cancer FDA NEWS RELEASE For Immediate Release: Feb. 22, 2013 Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA FDA approves...

About 7,500 attendees from more than 90 countries are expected to convene for the San Antonio Breast Cancer Symposium (SABCS), Dec. 6–10. SABCS is a comprehensive scientific meeting that provides the latest information on prevention, diagnosis, and treatment...

eribulin eribulin mesylate 13/9/2013 Halaven is a novel anticancer agent discovered and developed in-house by Eisai and is currently approved in more than 50 countries, including Japan, the United States and in Europe. In Russia, Halaven was approved...

But imaging experts stress that doing so may raise risk for actual breast cancer THURSDAY, Feb. 9, 2017 (HealthDay News) — The trauma of receiving a false-positive result from a mammogram may lead many women to delay or skip their next screening, a...

On Monday, the FDA gave its first approval to a pre-surgical breast cancer drug. The drug, Perjeta, manufactured by Roche had been previously approved for late-stage breast cancer last year. Accelerated approval of the drug for treating pre-surgical...